Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence
RK Vaddepally, P Kharel, R Pandey, R Garje… - Cancers, 2020 - mdpi.com
Cancer is associated with higher morbidity and mortality and is the second leading cause of
death in the US. Further, in some nations, cancer has overtaken heart disease as the …
death in the US. Further, in some nations, cancer has overtaken heart disease as the …
[HTML][HTML] Novel patterns of response under immunotherapy
E Borcoman, Y Kanjanapan, S Champiat, S Kato… - Annals of …, 2019 - Elsevier
Novel patterns of response and progression to immunotherapy have been reported that are
not observed with conventional cytotoxic or targeted anticancer treatments. A major …
not observed with conventional cytotoxic or targeted anticancer treatments. A major …
Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Bladder Cancer focuses on the clinical presentation and workup of suspected bladder …
for Bladder Cancer focuses on the clinical presentation and workup of suspected bladder …
Disulfidptosis classification of hepatocellular carcinoma reveals correlation with clinical prognosis and immune profile
T Wang, K Guo, D Zhang, H Wang, J Yin, H Cui… - International …, 2023 - Elsevier
A new mode of cell death, disulfidptosis, has been discovered. Clinical prognostic
significance of disulfidptosis related pattern in hepatocellular carcinoma (HCC). In this study …
significance of disulfidptosis related pattern in hepatocellular carcinoma (HCC). In this study …
Targeting programmed cell death-1 (PD-1) and ligand (PD-L1): a new era in cancer active immunotherapy
Improved understanding of the immune system and its role in cancer development and
progression has led to impressive advances in the field of cancer immunotherapy over the …
progression has led to impressive advances in the field of cancer immunotherapy over the …
Treatment after progression in the era of immunotherapy
Immunotherapy represents a paradigm shift in oncology treatment. The goal of
immunotherapy is to overcome immunosuppression induced by a tumour and its …
immunotherapy is to overcome immunosuppression induced by a tumour and its …
Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study
To parallelly compare the efficacy of neoadjuvant immunotherapy (tislelizumab),
neoadjuvant chemotherapy (gemcitabine and cisplatin), and neoadjuvant combination …
neoadjuvant chemotherapy (gemcitabine and cisplatin), and neoadjuvant combination …
PD-1/PD-L1 blockade: have we found the key to unleash the antitumor immune response?
ZY Xu-Monette, M Zhang, J Li, KH Young - Frontiers in immunology, 2017 - frontiersin.org
PD-1–PD-L1 interaction is known to drive T cell dysfunction, which can be blocked by anti-
PD-1/PD-L1 antibodies. However, studies have also shown that the function of the PD-1–PD …
PD-1/PD-L1 antibodies. However, studies have also shown that the function of the PD-1–PD …
Patterns of response and progression to immunotherapy
Patterns of response and progression to immunotherapy may differ from those observed with
drugs such as chemotherapy and molecularly targeted agents. Specifically, some patients …
drugs such as chemotherapy and molecularly targeted agents. Specifically, some patients …
The immune checkpoint PD-1 in natural killer cells: expression, function and targeting in tumour immunotherapy
Simple Summary Natural killer cells are innate cytotoxic lymphocytes that play a key role in
the anti-tumor immune response. In the tumor microenvironment, however, the effector …
the anti-tumor immune response. In the tumor microenvironment, however, the effector …